Neudle.com: sinemet

Differential
(Click to cross reference)

abdominal protrusion

acetylcholine

acromegaly

adolescent medicine

advances in neurology

adverse drug reaction

affective disorders

akathisia

akinesia of eyelid function

alcohol, neurologic complications with

alcoholism

algorithm

alien hand syndrome

alpha methyldopa hydrazine

amphetamines, dyskinesia associated with

amygdala

anasarca

anemia, iron deficiency

ankle edema

anticholinergic drugs

anticholinergic drugs, side effects of

apraxia of eyelid opening

apraxia, constructional

aprazolam

aqueduct of Sylvius, stenosis

arm swing, reduced

arrhythmia, cardiac

artane

arterial dissection, aorta, cerebral symptoms with

aspartate aminotransferase

aspiration

asterixis

ataxia

attention deficit disorder with hyperactivity

atypical

audiogram

auditory and vestibular pathways

autonomic cardiovascular reflexes

autonomic dysfunction

autonomic dysfunction, evaluation of

autonomic nervous system

axillary nerve

Babinski sign

ballismus, bilateral

basal ganglia, lesion, bilateral

brain transplantation

burst suppression pattern, electroencephalogram

CAT scan, emission, abnormal

catecholamine

catechol-o-methyltransferase inhibitor

cerebral autosomal dominate arteriopathy with subcortical infarction and leukoencephalopathy

cerebral cortical atrophy

cerebral infarction, subcortical

cerebral ischemia

cerebral palsy

cerebrospinal fluid

cerebrospinal fluid, abnormal

cerebrovascular accident

Charcot's sign

children

chorea

chromosomal abnormality

Clinical Pathologic Conference(C.P.C.)

controversies in neurology

Coombs test, positive

cortical-basal ganglionic degeneration

cyst, arachnoid, infant

dantrolene sodium

degenerative diseases of CNS

dementia, subcortical

dementia, treatment of

deprenyl

depression

desipramine

developmental milestones, loss of

differential diagnosis

dilantin

diplopia

disability rating scale, neurological

disability, neurological

diurnal variation

dopa responsive dystonia

dopamine

dopamine agonist

dopamine receptor

dopamine receptor, D2

drug induced neurologic disorders

dyskinesia, buccal lingual facial

dyskinesia, drug induced

dysphagia

dyspnea

dystonia

dystonia musculorum deformens

dystonia, children

dystonia, etiology of

dystonia, evaluation of

dystonia, focal

dystonia, painful

dystonia, prevalence of

dystonia, symptomatic

dystonia, treatment of

efficacy

electroencephalogram

electroencephalogram, abnormalities of

electroencephalogram, periodic complexes

electroencephalogram, triphasic delta waves

encephalopathy, progressive

epidemiology of neurology

extrapyramidal movement disorder, progressive

eye movement, disorders of

fine motor function, impaired

gamma amino butyric acid

gastrointestinal bleeding

gastrostomy

gaze palsy

gaze palsy, supranuclear

genetic neurologic disorders

genetic screening

genetic testing

Gilles de la Tourette syndrome

hallucination, visual

haloperidol

handwriting

head injury

head injury, brain stem lesion after

head injury, prognosis in

hepatic encephalopathy

hepatic encephalopathy, treatment of

hepatolenticular degeneration(Wilson's disease)

heralding manifestation

Huntington's chorea, presymptomatic detection of

hydrocephalus

hydroxyindole acetic acid 5(5HIAA)

iatrogenic neurologic disorders

inclusion bodies, intranuclear

intranasal medication

L-dopa, controlled release

L-dopa, delayed treatment in Parkinsonism

L-dopa, drug interactions with and side effects of

L-dopa, enteral infusion, continuous

L-dopa, intravenous

L-dopa, liquid

L-dopa, plasma concentration

L-dopa, potentiators of

Lewy body disease, diffuse

limbic system

lisuride

livedo reticularis

liver function enzymes

lobar atrophy

locus ceruleus, lesion of

lorazepam

madopar

manganese intoxication

memory, defect of recent

memory, impairment of

mental status, abnormal

methysergide

metoclopramide

microangiopathy, brain

migraine, treatment of

mimics

misdiagnosis

mitochondrial disease

molecular genetics

monoamine oxidase inhibitors

movement disorder, drug induced

movement disorder, extrapyramidal

movement disorder, treatment of

multiple sclerosis, diet in

multiple sclerosis, treatment of

multiple system atrophy

muscle atrophy, static

myasthenic syndrome, treatment of

neuroleptic malignant syndrome

neuroleptic sensitivity

neuroleptic, atypical

neurologic disease, diagnoses of

neurologic signs

neurologist

neuromyotonia

neuronal degeneration

neuronal intranuclear inclusion disease

neuroophthalmology

neuropathology

neuropathology, brain

neuropathy

neuropathy, peripheral

neuroprotective agents

nigrostriatal pathway

norepinephrine

nortriptyline

obsessive-compulsive disorder

occupational neurologic disorders

ocular myopathy

ocular myopathy, differential diagnosis

olanzapine

old age, neurology of

ondansetron

ophthalmoplegia

oral contraceptives

oral contraceptives, choreiform movements with

orthostatic hypotension

orthostatic hypotension, idiopathic

orthostatic hypotension, treatment of

parasympathetic nervous system

paresthesias

Parkinson disease

Parkinson disease, akinetic form

Parkinson disease, arteriosclerotic

Parkinson disease, axial symptoms

Parkinson disease, complications, late

Parkinson disease, dementia with

Parkinson disease, diagnosis

Parkinson disease, diet restricted in protein

Parkinson disease, differential diagnosis of

Parkinson disease, drug holiday

Parkinson disease, drug induced

Parkinson disease, dystonia with

Parkinson disease, early symptoms

Parkinson disease, etiology of

Parkinson disease, familial

Parkinson disease, fluctuations in

Parkinson disease, freezing phenomena in

Parkinson disease, heterogeneity of

Parkinson disease, juvenile

Parkinson disease, late onset

Parkinson disease, L-dopa nonresponsive

Parkinson disease, misdiagnosis

Parkinson disease, mode of onset

Parkinson disease, nonmotor problems of

Parkinson disease, on-off phenomena in

Parkinson disease, pathogenesis of

Parkinson disease, prognosis of

Parkinson disease, progression

Parkinson disease, rapid progression

Parkinson disease, sensory symptoms in

Parkinson disease, surgical treatment of

Parkinson disease, transient

Parkinson disease, treatment of

Parkinson disease, tremor, absence of

Parkinson disease, wearing off

Parkinson disease, young onset

Parkinsonism multiple-system atrophy

Parkinsonism plus syndrome

Parkinsonism syndrome

paroxetine

parsidol

pathologic gambling

patient information and support

penguin silhouette sign

pergolide

periodic limb movements

periodic movements during sleep

persistent vegetative state

personality change

phenothiazine

phenothiazine, dyskinesia associated with

pregnancy, neurologic complications in

pretectal syndrome

prevention of neurologic disorders

PRKN gene

procyclidine

prognosis

progressive neurologic disorder

progressive supranuclear palsy

psychiatric problems in neurologic disorders

psychological testing, neurologic problems

psychomotor retardation

pure autonomic failure

pyridoxine

pyridoxine deficiency

pyruvate-kinase deficiency anemia

reserpine and reserpine like drugs

respiratory dyskinesias

restless leg syndrome

retrocollis

retropulsion

reversible neurologic disorder

ropinirole, prolonged release

saccadic eye movements, abnormal

scoliosis

seizure

seizure, pyridoxine dependent

selective serotonin reuptake inhibitors

sequencing difficulty

serotonin

serum alanine aminotransferase

short stature

shunt procedure, ventricular-complications of

Shy-Drager syndrome

sinemet

single photon emission computed tomography

skin, biopsy

sleep

sleep pathology and physiology

small vessel disease

solvent

speech disorder

speech disorder, childhood

speech, soft

spinocerebellar ataxia

spinocerebellar ataxia type 1

spinocerebellar ataxia type 2

spinocerebellar ataxia type 3/Machado Joseph disease

Stalevo

stare

status epilepticus

stem cell transplantation

stereotyped behavior

stereotyped behavior, drug induced

stereotypy

steroid therapy, CNS treatment and complications with

stimulation, deep brain

subcortical U fibers

substantia nigra

subthalamic nucleus

subthalamic nucleus deep brain stimulation

sweating

sweating, abnormality of

sympathetic nervous system

sympathomimetic drugs

syncope

synucleinopathy

syphilis, neurologic complications with

toxins, nervous system

trauma

trazodone

treatment of neurologic disorder

tremor, thalamic stimulation for suppression of

tremor, treatment of

tricyclic antidepressant

trigeminal neuralgia

trinucleotide repeats

tripping

twins

tyrosine hydroxylase deficiency

upgaze, paralysis of

urinary incontinence

valium

varicella zoster virus

varicella zoster virus, encephalitis

vertigo, treatment of

vision, blurred

visual impairment

visual symptoms

visuospatial disturbance

walking, difficulty with

white matter disease, subcortical

Showing articles 150 to 200 of 233 << Previous Next >>

Controlled-Release Levodopa/Carbidopa. I. Sinemet CR3 Treatment of Response Fluctuations in Parkinson's Disease
Neurol 37:233-241, Cedarbaum,J.M.,et al, 1987

Controlled Release Levodopa Treatment of Motor Fluctuations in Parkinson's Disease
JNNP 50:194-198, Juncos,J.L.,et al, 1987

Factors that Influence the Occurrence of Response Variations in Parkinson's Disease
Ann Neurol 22:4-7, deJong,G.J.,et al, 1987

Multi-Center Study of Parkinson Mortality with Early Versus Later Dopa Treatment
Ann Neurol 22:8-12, Diamond,S.G.,et al, 1987

Early Combination of Bromocriptine & Levodopa in the Treatment of Parkinson's Disease:A 5-Year Follow-up
Neurol 37:826-828, Rinne,U.K., 1987

Forms of Dystonia in Patients with Parkinson's Disease
Neurol 37:1009-1011, Kidron,D.&Melamed,E., 1987

Parkinson's Disease & Motor Fluctuations:Long-Acting Carbidopa. Levodopa (CR-4-Sinemet)
Neurol 37:875-878, Goetz,C.G.,et al, 1987

Controlled-Release Levodopa/Carbidopa. II. Sinemet CR4 Treatment of Response Fluctuations in Parkinson's Disease
Neurol 37:1607-1612, Cedarbaum,J.M.,et al, 1987

Controlled Release Levodopa-Carbidopa (CR-5) in the Management of Parkinsonian Motor Fluctuations
Arch Neurol 44:1010-1012, Juncos,J.L.,et al, 1987

Dietary Influence on the Antiparkinsonian Response to Levodopa
Arch Neurol 44:1003-1005, Juncos,J.L.,et al, 1987

Levodopa Methyl Ester Treatment of Parkinson's Disease
Neurol 37:1242-1245, Juncos,J.L.,et al, 1987

Initiation of Levodopa Therapy in Parkinsonisn Patients Should be Delayed Until the Advanced Stages of the Disease
Arch Neurol 43:402-407, Melamen,E., 1986

Modification of Parkinson's Disease by Long-Term Levodopa Treatment
Arch Neurol 43:405-407, Markham,C.H.&Diamond,S.G., 1986

Painful Parkinson's Disease
Lancet 1:1366-1369, Quinn,N.P.,et al, 1986

Hereditary Dystonia-Parkinsonism Syndrome of Juvenile Onset
Neurol 36:1424-1428, Nygaard,T.C.&Duvoisin,R.C., 1986

Levodopa in Restless Legs
Lancet 2:426-427, vonScheele,C., 1986

Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986

A Neuroleptic Malignantlike Syndrome Due to Levodopa Therapy Withdrawal
JAMA 254:2792-2795, Friedman,J.H.,et al, 1985

L-Dopa-Induced Respiratory Disturbance in Parkinson's Disease Suppressed by Tiapride
Neurol 35:235-237, DeKeyser,J.,et al, 1985

Low Dosages of Bromocriptine Added to Levodopa in Parkinson's Disease
Neurol 35:199-206, Maier,M.M.,et al, 1985

Development of Malignant Melanoma after Levodopa Therapy for Parkinson's Disease, Report of Case & Review
Am J Med 79:119-121, Kochar,A.S., 1985

Levodopa & Melanoma:Three Cases & Review of Literature
JNNP 48:585-588, Rampen,F.H.J., 1985

Response Variations in the Treatment of Parkinson's Disease
Neurol 34:1507-1509, deJong,G.J.,et al, 1984

Pathologic Laughing & Crying Treated with Levodopa
Arch Neurol 41:1095-1096, Udaka,F.,et al, 1984

Chronic Low-Dose Levodopa Therapy in Parkinson's Disease:An Argument for Delaying Levodopa Therapy
Neurol 34:991-996, Rajput,A.H.,et al, 1984

Fatal Hyperpyrexia After Withdrawal of Levodopa
Neurol 34:249-251, Sechi,G.P.,et al, 1984

Skin Rash Associated with Sinemet 25/100
NEJM 309:1387-1388, Goetz,C.G., 1983

Alternate Day Levodopa Therapy in Parkinsonism
Neurol 32:324-326, Koller,W.C., 1982

False-Negative Results With Levodopa For Early Detection Of Huntington's Disease
NEJM 307:561-562, Myers,R.H.,et al, 1982

Meige's Syndrome During Long-term Dopaminergic Therapy in Parkinson's Disease
Arch Neurol 39:451-452, Weiner,W.J.,et al, 1982

Dystonia Musculorum Deformans, Implications of Therapeutic Response to Levodopa & Carbamazepine
Arch Neurol 39:376-377, Garg,B.P., 1982

Drug-induced Asterixis in Parkinson Disease
Neurol 32:553-555, Glantz,R.,et al, 1982

Lisuride Combined with Levodopa in Advanced Parkinson Disease
Neurol 31:1466-1469, Lieberman,A.N.,et al, 1981

Sinemet & the Treatment of Parkinsonism
Ann Int Med 94:364-370, Boshes,B., 1981

Evidence to Support Early Levodopa Therapy in Parkinson Disease
Neurol 31:125-131, Markham,C.H.,et al, 1981

Complications of Chronic Levodopa Therapy; Long-term Efficacy of Drug Holiday
Neurol 31:473-476, Koller,W.C.,et al, 1981

Levodopa & Presymptomatic Detection of Huntington's Disease-Eight-Year Follow-Up
NEJM 302:1090, Klawans,H.L.,et al, 1980

Increased Dosage of Carbidopa in Patients with Parkinson's Disease Receiving Low Doses of Levodopa
Arch Neurol 37:146-149, Hoehn,M.M., 1980

L-Dopa in Children with Progressive Neurological Disorders
Ann Neurol 7:93, Bugiani,O.,et al, 1980

Presymptomatic & Early Detection in Huntington's Disease
Ann Neurol 8:343-347, Klawans,H.L.,et al, 1980

Suppression of"Rubral"Tremor with Levodopa
BMJ 281:1043, Findley,L.J.,et al, 1980

Increased Ratio of Carbidopa to Levodopa in Treatment of Parkinson's Disease
Arch Neurol 37:723-726, Tourtellotte,W.W.,et al, 1980

Sinemet-25/100
Medical Letter, 22:511980., , 1980

L-Dopa Therapy in Parkinson's Disease:Plasma L-Dopa Concentr. Therapeutic Response, & Side Effects
Mayo Clin Proc 46:231-239, Muenter,M.D.,et al, 1979

Bromocriptine in Parkinson Disease:Further Studies
Neurol 29:363-369, Lieberman,A.N.,et al, 1979

Early-Morning Dystonia-A Late Side Effect of Long-Term Levodopa Therapy
Arch Neurol 36:308-310, Melamed,E., 1979

Considerations in the Management of Parkinsonism
Neurol 28:5, Fahn,S.,et al, 1978

Onset & End-of-dose Levodopa-induced Dyskinesias
Arch Neurol 35:261, Lhermitte,F.,et al, 1978

Comparative Effectiveness of Two Extracerebral DOPA Decarboxylase Inhibitors in Parkinson Disease
Neurol 28:964-968, Lieberman,A.,et al, 1978

Newer Concepts in Management of Migraine Headaches
J Med Soc N J 74:11, Haidri,N.H.,et al, 1977

Showing articles 150 to 200 of 233 << Previous Next >>